New roles for Joshua Smiley and Anat Ashkenazi at Lilly, as Thomas Grein retires
US pharma major Eli Lilly (NYSE: LLY) has announced that Joshua Smiley will be appointed to the post of senior vice president, finance, and treasurer effective October 1. Mr Smiley will replace Thomas Grein, who will retire in September after a 41-year career at Lilly.
Mr Smiley, who has been with Lilly for 21 years, currently serves as senior vice president, finance, and controller and chief financial officer for Lilly Research Laboratories (LRL). He will report to Derica Rice, executive vice president, global services, and chief financial officer.
Succeeding Mr Smiley will be Anat Ashkenazi, vice president, finance, and chief financial officer for Lilly Manufacturing, Global Quality and Lilly Diabetes. She has been with Lilly for 15 years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze